128 related articles for article (PubMed ID: 18391999)
21. Deal watch: AbbVie invests in pioneering celiac disease therapy.
Crunkhorn S
Nat Rev Drug Discov; 2013 Jul; 12(7):497. PubMed ID: 23812262
[No Abstract] [Full Text] [Related]
22. IL-1 trap go-ahead.
Ratner M
Nat Biotechnol; 2008 May; 26(5):485. PubMed ID: 18464767
[No Abstract] [Full Text] [Related]
23. Roger Perlmutter on shaping Amgen's R&D strategy. Interview by Christopher Watson.
Perlmutter RM
Drug Discov Today; 2005 Jun; 10(11):745-8. PubMed ID: 15922930
[No Abstract] [Full Text] [Related]
24. First-in-class anemia drug takes aim at Amgen's dominion.
Bouchie A
Nat Biotechnol; 2013 Nov; 31(11):948-9. PubMed ID: 24213751
[No Abstract] [Full Text] [Related]
25. The cost of bringing a radiopharmaceutical to the patient's bedside.
Nunn AD
J Nucl Med; 2007 Feb; 48(2):169. PubMed ID: 17268008
[No Abstract] [Full Text] [Related]
26. Biologics target bad bugs.
Extance A
Nat Rev Drug Discov; 2010 Mar; 9(3):177-8. PubMed ID: 20190776
[No Abstract] [Full Text] [Related]
27. What's fueling the biotech engine--2010 to 2011.
Aggarwal S
Nat Biotechnol; 2011 Dec; 29(12):1083-9. PubMed ID: 22158359
[No Abstract] [Full Text] [Related]
28. Tysabri's troubles return.
Hoag H
Nat Biotechnol; 2008 Oct; 26(10):1061. PubMed ID: 18846062
[No Abstract] [Full Text] [Related]
29. Deal watch: Bristol-Myers Squibb invests in cancer antibody that targets the innate immune system.
Nat Rev Drug Discov; 2011 Aug; 10(9):648. PubMed ID: 21878969
[No Abstract] [Full Text] [Related]
30. Pharma consolidates its grip on post-antibody landscape.
Sheridan C
Nat Biotechnol; 2007 Apr; 25(4):365-6. PubMed ID: 17420728
[No Abstract] [Full Text] [Related]
31. Therapeutic cancer vaccines.
Pijpers F; Faint R; Saini N
Nat Rev Drug Discov; 2005 Aug; 4(8):623-4. PubMed ID: 16106585
[No Abstract] [Full Text] [Related]
32. Are mAbs different?: a comment on Cohen and Wilson.
Neumann PJ
MAbs; 2009; 1(1):29-30. PubMed ID: 20046571
[No Abstract] [Full Text] [Related]
33. Heplisav's topline.
Aldridge S
Nat Biotechnol; 2008 Oct; 26(10):1058. PubMed ID: 18846058
[No Abstract] [Full Text] [Related]
34. Charity's first move is drug investment.
Mitchell P
Nat Med; 2002 Apr; 8(4):314. PubMed ID: 11927921
[No Abstract] [Full Text] [Related]
35. The bitterest pill.
Nature; 2006 Nov; 444(7119):532-3. PubMed ID: 17136064
[No Abstract] [Full Text] [Related]
36. Antibodies' long revenue stream spurs pharma acquisitions.
Mitchell P
Nat Biotechnol; 2007 Nov; 25(11):1194-5. PubMed ID: 17989656
[No Abstract] [Full Text] [Related]
37. Genmab signs cancer deal with Janssen.
Tung J
Bioanalysis; 2012 Oct; 4(19):2327. PubMed ID: 23251918
[No Abstract] [Full Text] [Related]
38. Amgen's bispecific antibody puffs across finish line.
Sheridan C
Nat Biotechnol; 2015 Mar; 33(3):219-21. PubMed ID: 25748895
[No Abstract] [Full Text] [Related]
39. Big Pharma's small wonder.
Fry E
Fortune; 2014 Jun; 169(8):178-84, 186. PubMed ID: 25211849
[No Abstract] [Full Text] [Related]
40. [Patients, patents and profits].
Haug C
Tidsskr Nor Laegeforen; 2007 Nov; 127(22):2921. PubMed ID: 18026234
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
